Now in it's 25th year, the PharmaTimes Marketer of the Year competition closes for entry on Friday 14th September - make sure you take advantage of this great opportunity for you and your team to compete, benchmark, learn and raise standards in pharma marketing.
US regulators have extended the review period for Roche’s application to market Tecentriq in combination with Avastin, carboplatin and paclitaxel for first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC).
Celltrion Healthcare is calling on the NHS to consider lowering the threshold for starting biologics in patients with rheumatoid arthritis (RA), and to put in place measures to boost patient access to such treatment.
New research has discovered a subset of men with prostate cancer who have specific faults in their tumours that significantly worsen their chances of survival, but could mean they are more likely to benefit from immunotherapy.
The National Institute for Health and Care Excellence (NICE) has changed its position on NHS funding for Kyowa Kirin International’s Crysvita, now endorsing the drug’s use to treat X-linked hypophosphataemia (XLH) in children and young people with growing bones in England and Wales.